by Lighthouse50
How many people have gotten HIV/Hep C from blood transfusion since testing began ?
I’m not sure about the number, but the chance is less than 1 case per million transfusions.
tried nejm.com? pubmed? who.org cdc.gov might also helpThere hasn’t been a documented cases of transmission via the blood supply since testing began in about 1985/6 for HIV (at least in Canada, not sure about the US).
The risk is very low now:
HIV – about 1 in 1.6 million with current testing...Read Full Story
Worldwide, exclusive deal signed with Genoscience and RFS Pharma for development and commercialization of BL-8030
Advantages of BL-8030 include high specificity, improved resistance profile, reduced toxicity and potentially reduced drug-drug interactions
JERUSALEM — (CRWENEWSWIRE) — BioLineRx (NASDAQ:BLRX) (TASE:BLRX), a biopharmaceutical development company, announced today it has signed a worldwide, exclusive license agreement with Genoscience and RFS Pharma to develop and commercialize...Read Full Story
Worldwide, exclusive deal signed with Genoscience and RFS Pharma for development and commercialization of BL-8030
Advantages of BL-8030 include high specificity, improved resistance profile, reduced toxicity and potentially reduced drug-drug interactions
JERUSALEM — (CRWENEWSWIRE) — BioLineRx (NASDAQ:BLRX) (TASE:BLRX), a biopharmaceutical development company, announced today it has signed a worldwide, exclusive license agreement with Genoscience and RFS Pharma to develop and commercialize...Read Full Story
Worldwide, exclusive deal signed with Genoscience and RFS Pharma for development and commercialization of BL-8030
Advantages of BL-8030 include high specificity, improved resistance profile, reduced toxicity and potentially reduced drug-drug interactions
JERUSALEM — (CRWENEWSWIRE) — BioLineRx (NASDAQ:BLRX) (TASE:BLRX), a biopharmaceutical development company, announced today it has signed a worldwide, exclusive license agreement with Genoscience and RFS Pharma to develop and commercialize...Read Full Story
Worldwide, exclusive deal signed with Genoscience and RFS Pharma for development and commercialization of BL-8030
Advantages of BL-8030 include high specificity, improved resistance profile, reduced toxicity and potentially reduced drug-drug interactions
JERUSALEM — (CRWENEWSWIRE) — BioLineRx (NASDAQ:BLRX) (TASE:BLRX), a biopharmaceutical development company, announced today it has signed a worldwide, exclusive license agreement with Genoscience and RFS Pharma to develop and commercialize...Read Full Story
NEW YORK (TheStreet) -- Why is everyone obsessed with hepatitis C? Initially described as "non-A/non-B," hepatitis C (HCV) didn't even have a proper name until the late 1980s, much less the rabid following the viral liver disease now enjoys in ...
Chronic hepatitis B virus (HBV) infection is a leading cause of cirrhosis and liver cancer worldwide; [1] the estimated prevalence in the United States is 0.3%–0.5%. [2] Each year, approximately 11,500–13,000 persons are newly reported with ...
The U.S. Food and Drug Administration said Thursday the use of Merck & Co.'s (MRK) Hepatitis C drug Victrelis with certain types of HIV medicines may reduce effectiveness of both types of treatments. Victrelis was approved last year to treat Hepatitis C, a liver disease caused by infection with the hepatitis C virus, which is transmitted through contaminated blood. Although Victrelis wasn't approved...
Combination therapy with pegylated interferon (PEG-IFN) and ribavirin long stood as the standard of care for chronic hepatitis C virus (HCV) infection. Although effective in achieving high rates of sustained virologic response (SVR), this ...
SAN DIEGO - February 7, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that a presentation of the Aethlon Hemopurifier to treat Hepatitis C virus (HCV) and other infectious disease conditions will occur at the upcoming 32nd Annual Dialysis Conference to be held...
A viral hepatitis caused by a single stranded RNA that is usually transmitted by exposure to blood products, such as during an injection of drugs, a blood transfusion, or other open blood and bodily fluids